この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
規制と法律 · 2015/9/291 分で読めます
Epi-Centers for the Prevention of Healthcare-Associated Infections, Antimicrobial Resistance and Adverse Events
ローカル自動翻訳 · 情報源の原言語
概要
The National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) will be providing a Single Source Competition Supplement to Harvard Pilgrim Healthcare, an awardee of the Epi-Centers for the Prevention of Healthcare-Associated Infections, Antimicrobial Resistance and Adverse Events Cooperative Agreement. The single source supplement will fund research utilizing proprietary methods to improve sepsis prevention by better defining the burden, preventability and identifying measurers to track progress.
情報源の原言語: Federal Register — All Documents原文の発表を開く →